Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
SNTA [NASD]
Synta Pharmaceuticals Corp.
Index- P/E- EPS (ttm)-1.27 Insider Own6.00% Shs Outstand91.64M Perf Week-4.11%
Market Cap363.81M Forward P/E- EPS next Y-1.23 Insider Trans5.54% Shs Float25.26M Perf Month-16.42%
Income-90.20M PEG- EPS next Q-0.29 Inst Own25.40% Short Float65.85% Perf Quarter-37.38%
Sales- P/S- EPS this Y-19.80% Inst Trans0.80% Short Ratio6.44 Perf Half Y-39.94%
Book/sh0.64 P/B6.20 EPS next Y-6.00% ROA-112.90% Target Price13.83 Perf Year-58.03%
Cash/sh1.00 P/C3.98 EPS next 5Y0.00% ROE-231.70% 52W Range3.70 - 10.72 Perf YTD-24.24%
Dividend- P/FCF- EPS past 5Y14.30% ROI- 52W High-62.97% Beta2.70
Dividend %- Quick Ratio2.90 Sales past 5Y- Gross Margin- 52W Low7.30% ATR0.31
Employees134 Current Ratio2.90 Sales Q/Q- Oper. Margin- RSI (14)35.63 Volatility5.78% 6.47%
OptionableYes Debt/Eq0.48 EPS Q/Q-6.90% Profit Margin- Rel Volume0.70 Prev Close4.04
ShortableYes LT Debt/Eq0.28 EarningsApr 28 Payout- Avg Volume2.58M Price3.97
Recom2.40 SMA20-8.40% SMA50-23.34% SMA200-28.62% Volume1,794,710 Change-1.73%
13-Mar-14Reiterated MLV & Co Buy $10 → $6
12-Mar-14Downgrade Stifel Hold → Sell
05-Nov-13Reiterated MLV & Co Buy $16 → $10
06-Jun-13Reiterated MLV & Co Buy $18.50 → $16
01-Apr-13Reiterated MLV & Co Buy $16 → $18.50
30-Aug-12Initiated Stifel Nicolaus Hold
05-Jan-12Initiated Rodman & Renshaw Mkt Outperform $8
14-Mar-11Reiterated Barclays Capital Equal Weight $2 → $4
28-Feb-11Upgrade Canaccord Genuity Hold → Buy $4.50 → $8
09-Nov-10Initiated MLV Capital Buy $8.50
26-Aug-10Initiated Morgan Joseph Buy $6
10-May-10Upgrade Roth Capital Hold → Buy $4
19-Feb-10Initiated RBC Capital Mkts Sector Perform $5
17-Feb-10Downgrade Roth Capital Buy → Hold $4
05-Nov-09Upgrade Roth Capital Hold → Buy $2 → $4
27-Feb-09Downgrade Wachovia Mkt Perform → Underperform
27-Feb-09Downgrade Roth Capital Buy → Hold $11 → $2
27-Feb-09Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
27-Feb-09Downgrade RBC Capital Mkts Outperform → Sector Perform
27-Feb-09Downgrade Lazard Capital Buy → Hold
15-Apr-14 10:43AM  Stocks: Insiders Buy at Opko Health and Conn's at Minyanville
10:43AM  Stocks: Insiders Buy at Opko Health and Conn's Inc. at Minyanville
14-Apr-14 08:37AM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial St EDGAR Online
08:00AM  Synta Pharmaceuticals Enters Into Agreement to Sell $5.0 Million in Common Stock Directly to an Affiliate of Synta Board Member Bruce Kovner Business Wire
07-Apr-14 07:30AM  Synta Announces Presentations at the 2014 Annual Meeting of the American Association of Cancer Research Business Wire
21-Mar-14 09:27AM  Synta Pharmaceuticals weakness overdone, says Roth Capital at theflyonthewall.com
05:44AM  Synta Pharmaceuticals Corp. (SNTA) Catches Eye: Stock Jumps 9.5% Zacks
20-Mar-14 08:02PM  Why Synta Pharmaceuticals, Herman Miller, and Tower Semiconductor Jumped Today at Motley Fool +9.47%
04:31PM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Sta EDGAR Online
02:34PM  Why Synta Pharmaceuticals Corp. Shares Soared at Motley Fool
05:45AM  Synta Announces Positive Interim Results from the ENCHANT-1 Trial of Ganetespib in Metastatic Breast Cancer at the 9th European Breast Cancer Conference Business Wire
19-Mar-14 08:50PM  Pharma Firms in Focus and Other #Stocks2Watch at Fox Business
14-Mar-14 01:04PM  SYNTA PHARMACEUTICALS CORP Financials EDGAR Online Financials
12-Mar-14 11:47AM  Why Synta Pharmaceuticals Corp. Plunged Today at Motley Fool -13.83%
11:47AM  Why Synta Pharmaceuticals Corp. Plunged Today
06:52AM  Synta Pharma downgraded by Stifel Briefing.com
11-Mar-14 02:55PM  Why Synta Pharmaceuticals Corp. Shares Jumped at Motley Fool
02:55PM  Why Synta Pharmaceuticals Corp. Shares Jumped
02:01PM  Synta Pharmaceuticals' Management Discusses Q4 2013 Results - Earnings Call Transcript at Seeking Alpha
02:01PM  Synta Pharmaceuticals' Management Discusses Q4 2013 Results - Earnings Call Transcript
10:00AM  Synta Pharmaceuticals Corp. Earnings Call scheduled for 10:00 am ET today CCBN
09:55AM  Synta Pharmaceuticals Corp. Discusses Q3 2013 Results (Webcast) at Seeking Alpha
09:55AM  Synta Pharmaceuticals Corp. Discusses Q3 2013 Results (Webcast)
07:07AM  Q4 2013 Synta Pharmaceuticals Corp. Earnings Release - Before Market Open CCBN
07:04AM  Synta Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Corporate Update Business Wire
07:04AM  Synta Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Corporate Update
07:02AM  Synta and QuantumLeap Healthcare Collaborative Announce Selection of Ganetespib for I-SPY 2 TRIAL in Breast Cancer Business Wire
07:02AM  Synta and QuantumLeap Healthcare Collaborative Announce Selection of Ganetespib for I-SPY 2 TRIAL in Breast Cancer
06:06AM  SYNTA PHARMACEUTICALS CORP Files SEC form 10-K, Annual Report EDGAR Online
06-Mar-14 06:46AM  Weakness Seen in Synta Pharmaceuticals (SNTA): Stock Tumbles 13.5% Zacks
04-Mar-14 05:01PM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events EDGAR Online
09:33AM  Synta Pharma CEO Sudden Resignation Might Trigger Overhaul at TheStreet
09:12AM  On The Fly: Pre-market Movers at theflyonthewall.com
08:30AM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Sta EDGAR Online
03-Mar-14 05:51PM  Synta CEO Bahcall Resigns as Board Panel to Run Drugmaker at Bloomberg
04:01PM  Synta Announces Executive Management Changes, Appoints Dr. Paul A. Friedman Director Business Wire
28-Feb-14 01:35PM  Synta to Present on Hsp90-inhibitor Drug Conjugate Platform at the 12th International Congress on Targeted Anticancer Therapies Business Wire -6.36%
27-Feb-14 04:05PM  Synta to Present at Upcoming Conferences Business Wire
26-Feb-14 04:05PM  Synta to Host Conference Call and Webcast of Fourth Quarter and Year-End 2013 Financial Results on March 11, 2014 Business Wire
25-Feb-14 06:41AM  Synta Pharmaceuticals (SNTA) Catches Eye: Stock Rises 8.9% Zacks
24-Feb-14 07:30AM  Synta Reports on Progress with Lead HDC Compounds at IASLC Conference Business Wire +8.85%
18-Feb-14 08:30AM  Synta Announces Upcoming Oral Presentations on Hsp90-Inhibitor Drug Conjugate (HDC) Platform Business Wire
10-Feb-14 10:22AM  Heres Why Synta Is a Good Play in the Cancer Meds Market at Wall St. Cheat Sheet +11.52%
03-Feb-14 05:36AM  Should You Worry About the Short Interest in Synta Pharmaceuticals (SNTA)? Zacks -6.74%
05:36AM  Should You Worry About the Short Interest in Synta Pharmaceuticals (SNTA)?
27-Jan-14 09:04AM  Synta Pharmaceuticals provides update on Q4 operations and reserves theflyonthewall.com -10.51%
10-Jan-14 01:00PM  Midday movers: Target, Blackberry, Pfizer & More at CNBC +10.82%
01:00PM  Midday movers: Target, Blackberry, Pfizer & More
10:16AM  Keep a Close Watch on Synta Pharmaceuticals Corp., Raptor Pharmaceuticals Corp. and AngioDynamics, Inc. Today at Motley Fool
10:16AM  Keep a Close Watch on Synta Pharmaceuticals Corp., Raptor Pharmaceuticals Corp. and AngioDynamics, Inc. Today
09-Jan-14 04:06PM  Synta Announces Launch of GANNET53, a Randomized, pan-European Study of Ganetespib in p53 Mutant, Metastatic Ovarian Cancer Business Wire
04:06PM  Synta Announces Launch of GANNET53, a Randomized, pan-European Study of Ganetespib in p53 Mutant, Metastatic Ovarian Cancer
04:05PM  Synta Announces Initiation of Three Multicenter, Randomized Phase II/III Trials of Ganetespib in Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Business Wire
04:05PM  Synta Announces Initiation of Three Multicenter, Randomized Phase II/III Trials of Ganetespib in Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
08-Jan-14 09:06AM  Sorrento Therapeutics appoints Amar Singh as Chief Business Officer theflyonthewall.com
09:06AM  Sorrento Therapeutics appoints Amar Singh as Chief Business Officer
07-Jan-14 05:16PM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events EDGAR Online
05:16PM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events
06-Jan-14 04:51AM  Synta Pharmaceuticals Corp. (SNTA) Catches Eye: Stock Surges 11.8% Zacks
04:51AM  Synta Pharmaceuticals Corp. (SNTA) Catches Eye: Stock Surges 11.8%
30-Dec-13 03:05PM  Investing In The Future Of Cancer Therapy: Synta A Top 2014 Pick at Seeking Alpha
03:05PM  Investing In The Future Of Cancer Therapy: Synta A Top 2014 Pick
20-Dec-13 04:15PM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online +9.44%
04:15PM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:30AM  Synta Announces Appointment of Steven Bernitz as Senior Vice President, Corporate Development Business Wire
08:30AM  Synta Announces Appointment of Steven Bernitz as Senior Vice President, Corporate Development
18-Dec-13 12:36PM  Synta Pharmaceuticals: 4 Key Investing Takeaways From 2013 at Motley Fool
16-Dec-13 08:31AM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
12-Dec-13 02:27PM  More Good News: Synta Pharmaceuticals Could Be A Triple Bagger at Seeking Alpha
08:32AM  Synta Pharmaceuticals announces interim results from ENCHANT-1 Ganetespib trial theflyonthewall.com
08:30AM  Synta Announces Positive Interim Results from the ENCHANT-1 Trial of Ganetespib in Metastatic Breast Cancer at the 2013 San Antonio Breast Cancer Symposium Business Wire
02-Dec-13 04:16PM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E EDGAR Online
22-Nov-13 10:54AM  2 Speculative Biopharmas Way Under Analyst Price Targets at Seeking Alpha
21-Nov-13 04:41PM  InPlay: Synta Pharma announces publications demonstrating ganetespib activity in triple-negative breast cancer models Briefing.com
04:40PM  Synta Announces Publications Demonstrating Ganetespib Activity in Triple-Negative Breast Cancer Models Business Wire
19-Nov-13 06:11AM  Synta Pharmaceuticals (SNTA) Catches Eye: Stock Surges 15.2% Zacks +7.80%
18-Nov-13 05:16PM  Why Voxeljet, Synta Pharmaceuticals, and The Container Store Are Today's 3 Best Stocks at Motley Fool +15.13%
04:29PM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
10:35AM  Insiders Buy Shares at Synta Pharmaceuticals and Aircastle at Minyanville
10:10AM  Synta Pharmaceuticals Closes Public Offering of Common Stock Business Wire
05:26AM  Insiders Are Buying Synta Pharmaceuticals at Seeking Alpha
14-Nov-13 06:01AM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial St EDGAR Online +5.03%
13-Nov-13 03:04PM  Why Synta Pharmaceuticals Is Poised To Be The Next Celldex at Seeking Alpha -11.27%
09:02AM  InPlay: Synta Pharmaceuticals announced that it has priced an underwritten public offering of 14 mln shares of its common stock at a price to the public of $3.75/share Briefing.com
09:00AM  Synta Pharmaceuticals Prices Public Offering of Common Stock Business Wire
12-Nov-13 04:02PM  InPlay: Synta Pharma announces proposed public offering of common stock; size not disclosed Briefing.com +5.19%
04:01PM  Synta Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire
06:49AM  Synta Pharmaceuticals Corp. is now in Oversold Territory Zacks
07-Nov-13 01:05PM  SYNTA PHARMACEUTICALS CORP Financials EDGAR Online Financials
04-Nov-13 04:27PM  Synta Pharma skids after expanding drug study AP
01:40PM  Synta Pharmaceuticals Management Discusses Q3 2013 Results - Earnings Call Transcript at Seeking Alpha
10:00AM  Synta Pharmaceuticals Corp. Earnings Call scheduled for 10:00 am ET today CCBN
07:35AM  Synta Pharmaceuticals Corp. Earnings Call scheduled for 10:00 am ET today CCBN
07:07AM  Q3 2013 Synta Pharmaceuticals Corp. Earnings Release - Before Market Open CCBN
06:40AM  Synta Provides Clinical Updates and Reports Third Quarter 2013 Financial Results Business Wire
06:07AM  SYNTA PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report EDGAR Online
02-Nov-13 03:20PM  This Week in Biotech at Motley Fool
10:20AM  3 Horrendous Health-Care Stocks This Week at Motley Fool
31-Oct-13 08:13AM  Synta announces publication of Hsp90-inhibitor first patent application theflyonthewall.com
08:09AM  InPlay: Synta Pharma announces publication of first patent application covering its Hsp90-inhibitor Drug Conjugate (HDC) platform Briefing.com
Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs for treating severe medical conditions, including cancer and chronic inflammatory diseases. The company has two drug candidates in clinical trials for treating multiple types of cancer and various drug candidates in the preclinical stage of development. Its lead drug candidate includes ganetespib, an Hsp90 inhibitor, which is in Phase III clinical trial for the treatment of non-small cell lung cancer; in Phase II clinical trial for patients with hormone receptor positive metastatic breast cancer; in Phase I clinical trial for the treatment of HER2 positive patients with metastatic breast cancer; in Phase II/III clinical trial for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome; and in Phase I/II trial of paclitaxel in combination with ganetespib in patients with platinum-resistant ovarian cancer. The company's product pipeline also comprises Hsp90-inhibitor Drug Conjugate, a novel, proprietary small molecule cancer drug development program; and Elesclomol, a mitochondria-targeting agent that is in Phase 2 clinical trial for ovarian cancer. Its product pipeline in preclinical development stage for inflammatory diseases includes CRACM ion channel inhibitors for rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, allergy, transplant rejection, and other autoimmune diseases and inflammatory conditions; and IL-12/23 inhibitors for inflammatory and autoimmune diseases. Synta Pharmaceuticals Corp. was incorporated in 2000 and is based in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kovner BruceDirectorApr 11Buy4.011,250,0005,012,5008,121,467Apr 14 07:34 PM
Bahcall Safi RPresident and CEONov 13Buy3.7520,00075,0002,053,135Nov 15 06:03 PM
REARDON WILLIAM SDirectorNov 13Buy3.7513,33349,99936,561Nov 15 06:01 PM
Gollust Keith RDirectorNov 13Buy3.75150,000562,5002,823,383Nov 15 05:58 PM
Kovner BruceDirectorNov 13Buy3.755,000,00018,750,0007,649,803Nov 15 05:56 PM
Bahcall Safi RPresident and CEOJun 28Buy5.0310,00050,2992,033,135Jul 01 08:28 AM
Kovner BruceDirectorJun 27Buy4.71150,000706,5153,100,000Jul 01 05:55 PM
Kovner BruceDirectorJun 26Buy4.65300,0001,395,9302,950,000Jun 27 05:52 PM
Kovner BruceDirectorJun 25Buy4.35200,000869,4602,650,000Jun 27 05:52 PM
Kovner BruceDirectorJun 24Buy4.43200,000885,9202,450,000Jun 25 04:42 PM
Bahcall Safi RPresident and CEOJun 21Buy4.1220,00082,3742,023,135Jun 24 08:01 AM
Kovner BruceDirectorJun 21Buy4.2350,000211,5202,250,000Jun 25 04:42 PM
Kovner BruceDirectorJun 18Buy4.00200,000799,1602,200,000Jun 20 04:44 PM
Bahcall Safi RPresident and CEOJun 14Buy4.0610,00040,5502,003,135Jun 17 08:02 AM
Bahcall Safi RPresident and CEOJun 06Buy4.0410,00040,3901,993,135Jun 06 05:19 PM
Kovner BruceDirectorJun 06Buy4.31738,9003,186,9502,000,000Jun 06 05:10 PM
Kovner BruceDirectorJun 05Buy4.71756,0003,561,7431,261,100Jun 06 05:10 PM
Vukovic VojoSVP, Chief Medical OfficerJun 05Buy4.5810,00045,80035,249Jun 06 05:04 PM
WILSON ROBERT NDirectorJun 04Buy5.0010,00050,000699,679Jun 06 05:01 PM
Kovner BruceDirectorJun 04Buy4.99505,1002,521,661505,100Jun 06 05:10 PM